Kazia selected as top-10 finalist in the ANZLF Trans-Tasman Innovation & Growth Awards

Kazia is pleased to announce they have been selected as a top-10 finalist in the ANZLF Trans-Tasman Innovation & Growth Awards.

The Awards celebrate the innovation, growth and impact of emerging businesses in Australia and New Zealand and Kazia was recognised for its strong growth story, diverse and collaborative culture and its innovative programs for brain and ovarian cancer.

The Awards are run by the Australia New Zealand Leadership Forum (ANZLF) which brings senior business and government leaders together to help Australia and New Zealand prosper in the global economy.

The four Award winners will be announced at a dinner in Auckland, New Zealand next Thursday, September 12. The Awards will be presented by New Zealand Prime Minister, Jacinda Ardern.

For more information on Kazia register your interest below.

Register Interest

 

About Kazia Therapeutics (ASX: KZA)

Kazia Therapeutics is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. Headquartered
in Sydney, Australia, Kazia Therapeutics collaborates with leading scientists, clinicians, and investors around the world.